Research use onlyNot for human or veterinary use
Encore Bio Labs CartExplore catalog
ENCORE BIO LABSRESEARCH COLLECTION
Retatrutide — complete Encore Bio Labs reference vialMATERIAL / 17

Reference artwork · Legacy packaging may be shown.
Listed identity and formats take precedence over the image.

Research material

Retatrutide

Three receptors. One connected view of metabolism. Retatrutide, also known as LY3437943, is investigated at GLP-1, GIP and glucagon receptors. One molecule to explore three key pathways in metabolism.

CAS
2381089-83-2

Formats & reference pricing

USD
Listed formatReference price
10 mg$89 USD
15 mg$109 USD
20 mg$129 USD
30 mg$169 USD
40 mg$209 USD
50 mg$249 USD
60 mg$289 USD
100 mg$449 USD

Reference prices describe the listed formats. They do not confirm availability or constitute an offer for sale.

Review product documentation

For laboratory research only. Not for human or veterinary use.

About the reference identity

A research code and a modified peptide chain

Retatrutide also appears in scientific records as LY3437943. Published structural descriptions show a 39-amino-acid chain with modified residues and an attached 20-carbon fatty-diacid group. These details distinguish the reference molecule from an unmodified peptide sequence; they are molecular descriptors, not findings from an Encore vial test.

Development code
LY3437943
Reference structure
39 residues with a 20-carbon fatty-diacid group

Reference identity only; not a test result for current inventory.

01 / Material overview

The specifications.

Catalog identity
Retatrutide
CAS
2381089-83-2
Listed formats
10 mg · 15 mg · 20 mg · 30 mg · 40 mg · 50 mg · 60 mg · 100 mg
Reference price range
$89–$449 USD
Intended setting
Qualified laboratory or institutional research
Inventory specifications
Independent inventory review pending

02 / Public research context

Identity and development status.

Public records can identify the investigational molecule and its development status. They do not verify a current catalog lot.

INVESTIGATIONAL REFERENCE · STATUS REVIEWED OCT 2026LY3437943

Retatrutide remains investigational.

Public records identify retatrutide, also known by the development code LY3437943, as an investigational molecule. It is not FDA-approved. Registered clinical studies describe sponsor-controlled clinical development and must not be read as evidence about the identity, quality, or suitability of this catalog material.

Catalog identity
Retatrutide
Development code
LY3437943
CAS
2381089-83-2
Regulatory status
Investigational · Not FDA-approved
Clinical-trial equivalence
Not represented or established
Scope of this reference

This section is limited to public identity and development-status information. Equivalence to sponsor clinical-trial material is not established. It makes no efficacy, weight-loss, glycemic, therapeutic, safety, dosing, preparation, reconstitution, administration, or medical-use claim for the material listed on this site.

External public records

PubChem · Retatrutide identity record ClinicalTrials.gov · TRIUMPH-1 registry FDA · Public regulatory-status information Eli Lilly · Investigational-status FAQ

03 / Supporting records

Documentation.

Read the Encore summary, the scope of related reports and the status of privacy-redacted supplier copies.

No authenticated certificate establishing current-inventory identity or specifications is published for Retatrutide in this catalog.

Encore documentary summary · not a laboratory-issued COA

View Retatrutide PDF downloads ↓
Report availability
9 related reports located
Formats & scope
Related reports name 10, 15, 20, 30 and 40 mg samples. No 50 mg, 60 mg or 100 mg report was located. Eleven source files represent nine distinct report records; two are alternate-format copies, not additional tests.
Report authenticity
Laboratory authentication pending
Inventory evidence review
Report-to-inventory correspondence has not been independently established. No purity, quantity or activity result is attributed to current inventory.
Outstanding review
Keep sample results separate. One 30 mg report states a measured amount outside its own stated acceptance range. Other quantity differences also need clarification; the 10 mg identity/purity report does not measure net content.
Product-specific SDS
Not located in the reviewed PDF set; applicability and verification pending.

Document inventory reviewed October 6, 2026. Related reports were commissioned by third parties, not Encore. Original customer details and internal records are not included here.

Privacy-redacted supplier report

Supplier-provided laboratory report

Where prepared, these are copies redacted by Encore for privacy, not laboratory-issued public versions or Encore-commissioned tests. Analytical content is not replaced with Encore results.

Retatrutide · Related reports

3 reports · PDF available

English original · 6 pages · 3.7 MB

Open PDF Download PDF

Spanish translation · 12 pages · 3.7 MB

Open Spanish PDF Download Spanish PDF

Open PDF uses a new tab. Download PDF saves the same privacy-redacted packet.

Prepared by Encore; not issued or certified by the laboratory. Each translated page is followed by its English source page, preserving original graphs and signatures. The separate English original is unchanged.

Included scope and exclusions: Selected reports name 10 mg and 20 mg samples. The MZ 10 mg report covers identity/purity, not net content. A separate 30 mg report states 36 mg / 120%, outside its printed 90-110% range; it remains unresolved and is not included here. Other quantity differences remain unresolved. No 25 mg report was located.

Laboratory authentication pending. These related references are not independently authenticated certificates for current Encore inventory. Supplier confirmation does not resolve the scope or discrepancies listed above.

Copy preparation
11 source files in redacted review copies. Duplicate file formats are not additional tests.
Supplier sharing permission
Owner-confirmed for supplied reports; this does not imply a report exists for every product. Report authentication is a separate check.
Privacy review
Selected website copy redacted; residual identification risk remains. Retained references and copies elsewhere can still identify the original customer; redaction does not guarantee anonymity.
Downloads
Selected related-reference PDF available.
Laboratory-issued public copy
Not available. Encore-prepared redactions are not an issuer reissue.

Read the packet cover and each report’s scope and limitations. Outstanding review items above remain unresolved; PDF availability does not change verification status.

A public copy does not by itself verify current inventory. No laboratory replacement or delivery date is promised.

Explore summary & report status

04 / A closer look

Common questions.

01Which Retatrutide formats and reference prices are listed?

10 mg: $89 USD; 15 mg: $109 USD; 20 mg: $129 USD; 30 mg: $169 USD; 40 mg: $209 USD; 50 mg: $249 USD; 60 mg: $289 USD; 100 mg: $449 USD. These are catalog quantities and reference prices, not usage instructions, stock confirmation or an offer for sale.

02Where can I find the Retatrutide reports?

The Documentation section on this page includes Open PDF and Download PDF links to a 6-page English original containing 3 supplier-provided reports. Read the covered sample formats and limitations beside the download. These privacy-redacted, third-party-commissioned copies are not laboratory reissues. Laboratory authentication and independent inventory review remain pending.

03Is retatrutide FDA-approved?

No. As of October 2026, retatrutide remains investigational and is not FDA-approved. Public clinical-trial records describe the sponsor-controlled development program; they do not establish approval, availability for public use, or suitability of this catalog material.

04Is this catalog material represented as the same material used in clinical trials?

No. This site makes no equivalence claim. Public records about LY3437943 describe an investigational molecule and sponsor-controlled clinical-trial material. They do not verify the identity, purity, sterility, potency, formulation, or suitability of any current Encore Bio Labs catalog lot.

05Does this page provide dosing, reconstitution, preparation, or administration guidance?

No. This catalog does not provide dosing, reconstitution, preparation, administration, personal-use, or medical guidance. Listed quantities are catalog formats only.

06Does the image establish the contents of a lot?

No. The image is owned Encore Bio Labs reference artwork and may show legacy packaging. Use the written identity and specifications, then verify the exact lot with supporting records.

Continue the collection

Next in the catalog.

View all materials